Cargando…

Pheochromocytomas and secreting paragangliomas

Catecholamine-producing tumors may arise in the adrenal medulla (pheochromocytomas) or in extraadrenal chromaffin cells (secreting paragangliomas). Their prevalence is about 0.1% in patients with hypertension and 4% in patients with a fortuitously discovered adrenal mass. An increase in the producti...

Descripción completa

Detalles Bibliográficos
Autores principales: Plouin, Pierre-François, Gimenez-Roqueplo, Anne-Paule
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1702343/
https://www.ncbi.nlm.nih.gov/pubmed/17156452
http://dx.doi.org/10.1186/1750-1172-1-49
_version_ 1782131250177245184
author Plouin, Pierre-François
Gimenez-Roqueplo, Anne-Paule
author_facet Plouin, Pierre-François
Gimenez-Roqueplo, Anne-Paule
author_sort Plouin, Pierre-François
collection PubMed
description Catecholamine-producing tumors may arise in the adrenal medulla (pheochromocytomas) or in extraadrenal chromaffin cells (secreting paragangliomas). Their prevalence is about 0.1% in patients with hypertension and 4% in patients with a fortuitously discovered adrenal mass. An increase in the production of catecholamines causes symptoms (mainly headaches, palpitations and excess sweating) and signs (mainly hypertension, weight loss and diabetes) reflecting the effects of epinephrine and norepinephrine on α- and β-adrenergic receptors. Catecholamine-producing tumors mimic paroxysmal conditions with hypertension and/or cardiac rhythm disorders, including panic attacks, in which sympathetic activation linked to anxiety reproduces the same signs and symptoms. These tumors may be sporadic or part of any of several genetic diseases: familial pheochromocytoma-paraganglioma syndromes, multiple endocrine neoplasia type 2, neurofibromatosis 1 and von Hippel-Lindau disease. Familial cases are diagnosed earlier and are more frequently bilateral and recurring than sporadic cases. The most specific and sensitive diagnostic test for the tumor is the determination of plasma or urinary metanephrines. The tumor can be located by computed tomography, magnetic resonance imaging and metaiodobenzylguanidine scintigraphy. Treatment requires resection of the tumor, generally by laparoscopic surgery. About 10% of tumors are malignant either at first operation or during follow-up, malignancy being diagnosed by the presence of lymph node, visceral or bone metastases. Recurrences and malignancy are more frequent in cases with large or extraadrenal tumors. Patients, especially those with familial or extraadrenal tumors, should be followed-up indefinitely.
format Text
id pubmed-1702343
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-17023432006-12-15 Pheochromocytomas and secreting paragangliomas Plouin, Pierre-François Gimenez-Roqueplo, Anne-Paule Orphanet J Rare Dis Review Catecholamine-producing tumors may arise in the adrenal medulla (pheochromocytomas) or in extraadrenal chromaffin cells (secreting paragangliomas). Their prevalence is about 0.1% in patients with hypertension and 4% in patients with a fortuitously discovered adrenal mass. An increase in the production of catecholamines causes symptoms (mainly headaches, palpitations and excess sweating) and signs (mainly hypertension, weight loss and diabetes) reflecting the effects of epinephrine and norepinephrine on α- and β-adrenergic receptors. Catecholamine-producing tumors mimic paroxysmal conditions with hypertension and/or cardiac rhythm disorders, including panic attacks, in which sympathetic activation linked to anxiety reproduces the same signs and symptoms. These tumors may be sporadic or part of any of several genetic diseases: familial pheochromocytoma-paraganglioma syndromes, multiple endocrine neoplasia type 2, neurofibromatosis 1 and von Hippel-Lindau disease. Familial cases are diagnosed earlier and are more frequently bilateral and recurring than sporadic cases. The most specific and sensitive diagnostic test for the tumor is the determination of plasma or urinary metanephrines. The tumor can be located by computed tomography, magnetic resonance imaging and metaiodobenzylguanidine scintigraphy. Treatment requires resection of the tumor, generally by laparoscopic surgery. About 10% of tumors are malignant either at first operation or during follow-up, malignancy being diagnosed by the presence of lymph node, visceral or bone metastases. Recurrences and malignancy are more frequent in cases with large or extraadrenal tumors. Patients, especially those with familial or extraadrenal tumors, should be followed-up indefinitely. BioMed Central 2006-12-08 /pmc/articles/PMC1702343/ /pubmed/17156452 http://dx.doi.org/10.1186/1750-1172-1-49 Text en Copyright © 2006 Plouin and Gimenez-Roqueplo; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Plouin, Pierre-François
Gimenez-Roqueplo, Anne-Paule
Pheochromocytomas and secreting paragangliomas
title Pheochromocytomas and secreting paragangliomas
title_full Pheochromocytomas and secreting paragangliomas
title_fullStr Pheochromocytomas and secreting paragangliomas
title_full_unstemmed Pheochromocytomas and secreting paragangliomas
title_short Pheochromocytomas and secreting paragangliomas
title_sort pheochromocytomas and secreting paragangliomas
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1702343/
https://www.ncbi.nlm.nih.gov/pubmed/17156452
http://dx.doi.org/10.1186/1750-1172-1-49
work_keys_str_mv AT plouinpierrefrancois pheochromocytomasandsecretingparagangliomas
AT gimenezroqueploannepaule pheochromocytomasandsecretingparagangliomas